Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone for Prevention of Paradoxical IRIS in AIDS Patients
NCT07565623Not yet recruiting
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
01
Overview
Randomised, open-label trial of prednisolone in immune reconstitution inflammatory syndrome (IRIS) (2 arms). Primary endpoint: Incidence rate of paradoxical IRIS at 12 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
prednisolone
03
Conditions
immune reconstitution inflammatory syndrome (IRIS)
Beyond the preview
Go deeper on NCT07565623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565623.